Open AccessFarnesoid X receptor: Acting through bile acids to treat metabolic disorders
Author(s) -
Yanqiao Zhang
Publication year - 2010
Publication title -
drugs of the future
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.115
H-Index - 43
eISSN - 2013-0368
pISSN - 0377-8282
DOI - 10.1358/dof.2010.035.08.1520865
Subject(s) - farnesoid x receptor , bile acid , nuclear receptor , g protein coupled bile acid receptor , metabolic pathway , superfamily , chemistry , receptor , metabolism , biochemistry , biology , transcription factor , gene
Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily and plays an important role in maintaining bile acid, lipid and glucose homeostasis. Bile acids are endogenous ligands for FXR. However, bile acids may also activate pathways independent of FXR. The development of specific FXR agonists has provided important insights into the role of FXR in metabolism. Recent data have demonstrated that FXR is a therapeutic target for treatment of certain metabolic disorders. This review will focus on recent advances in the role of FXR in metabolic disease.